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Background
Omalizumab is a recombinant monoclonal anti-immuno-
globulin (Ig)E antibody (Ab), approved for treatment of
severe asthma. The mechanisms by which is effective in
asthma control are not yet fully understood but is known
that it has an anti-inflammatory effect conducting to
important clinical benefits. Urine sample collection is the
least invasive form for biofluid sampling. The analysis of
metabolomic urine profile in asthmatic patients under-
going omalizumab may add important data to the current
knowledge.
Method
Case report: We present the case of a 48 year old woman,
with severe persistent allergic asthma, despite level 4
(GINA) medical treatment, who initiated omalizumab in
order to control her nocturnal symptoms and her frequent
unscheduled medical visits. Before treatment and at
12 weeks: clinical evaluation with ACT was registered;
lung function, FeNO, IgE and eosinophils were measured.
Two-dimensional gas chromatography (GC ´GC-ToFMS)
combined with headspace solid phase microextraction
(HS-SPME) was applied to the untargeted study of the
volatile metabolomic urine profile.
Results
The patient showed a good clinical response: ACT
improved from 16 to 22, with nocturnal and effort symp-
toms control, without any unscheduled medical visit,
showing a stable lung function, despite an imprudent auto
stepped-down inhaler treatment. Regarding metabolomic
urine profile, the present work was focused on aldehydes
and alkanes (metabolites possibly linked to oxidative stress
and/or inflammation processes). Previously to treatment,
the urine profile was mainly characterized by alkanes; after
treatment aldehydes had a major importance in the char-
acterization of urine composition.
Conclusions
Beeing alkanes end-compounds in the sequence of oxida-
tion reactions, it can indicate that oxidative state is at a
higher extent before treatment, when compared to urine
profile after treatment. In spite of being a case-study, the
results suggest that the urinary volatile profiles obtained
by HS-SPME/GC´ GC-ToFMS may be useful for differen-
tiating subjects with different physiological conditions,
thus making it worth to further explore its diagnostic
potential and follow-up therapy effects.
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